The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...

Ziftomenib is the first Menin inhibitor approved for relapsed or refractory mutant nucleophosmin 1 acute myeloid leukemia, showing promising efficacy in clinical trials. The phase 2 KOMET-001 trial ...

In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

International collaboration is crucial for enhancing rural cancer care, with shared experiences and solutions from across the ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies. The FDA has approved the OncoMate® MSI Dx ...

The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...

Targeted Therapies in Oncology | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine ...

The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...

El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC. Immunotherapy has become a ...

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...